

# Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Amoxicillin/clavulanate 500mg/125mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
Bedaquiline 20mg tablet	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes
Bedaquiline 100mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Clofazimine 50mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Cycloserine 125mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Delamanid 25mg dispersible tablet	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	No	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

# Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
												<ul style="list-style-type: none"> <li><span style="color: green;">●</span> Yes</li> <li><span style="color: red;">●</span> No</li> <li><span style="color: blue;">●</span> Ineligible for inclusion</li> <li><span style="color: gray;">●</span> N/A</li> </ul>
Delamanid 50mg dispersible tablet	●	●	●	●	●	●	●	●	●	●	●	
Delamanid 50mg tablet	●	●	●	●	●	●	●	●	●	●	●	
Ethambutol 25mg/mL oral liquid	●	●	●	●	●	●	●	●	●	●	●	
Ethambutol 50mg dispersible tablet	●	●	●	●	●	●	●	●	●	●	●	
Ethambutol 100mg dispersible tablet	●	●	●	●	●	●	●	●	●	●	●	
Ethambutol 100mg tablet	●	●	●	●	●	●	●	●	●	●	●	
Ethionamide 125mg dispersible tablet	●	●	●	●	●	●	●	●	●	●	●	

DR-TB: Drug-Resistant TB  
 EML: Essential Medicines List  
 EOI: Expression of Interest  
 ERP: Expert Review Panel  
 SRA: Stringent Regulatory Authority  
 WHO PQ: World Health Organization Prequalification of Medicines Programme  
 Version: February 2023

# Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Ethionamide 125mg tablet/capsule	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	No
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	No
Isoniazid 50mg/5mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Levofloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

**Status**  
● Yes  
● No  
● Ineligible for inclusion  
● N/A

DR-TB: Drug-Resistant TB  
 EML: Essential Medicines List  
 EOI: Expression of Interest  
 ERP: Expert Review Panel  
 SRA: Stringent Regulatory Authority  
 WHO PQ: World Health Organization Prequalification of Medicines Programme  
 Version: February 2023

# Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Linezolid 20mg/mL oral suspension	Yes	Yes	Yes	Yes	Yes	No	No	No	No	Ineligible for inclusion	No	No
Linezolid 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Linezolid 600mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Meropenem 500mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Meropenem 1000mg vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Meropenem/clavulanate 1000 mg/125 mg vial	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No
Moxifloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

# Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Moxifloxacin 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
PAS 4gm granules	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
PAS Sodium 4gm/5.52gm powder	Yes	Yes	No	No	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Pyrazinamide 30mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Pyrazinamide 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023